Browse the evidence

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with Type 2 Diabetes, with specific benefits on stroke and weight loss.

If you have Type 2 Diabetes and are at high risk for heart attack or stroke, ask your doctor about GLP-1 receptor agonists (like Victoza, Ozempic, or Trulicity). These medications have been proven to significantly reduce the risk of major cardiovascular events and stroke. They also promote weight loss, which is an added benefit. They are available as injections (daily or weekly) and in some cases, oral tablets.

Icosapent ethyl (pure EPA) reduces cardiovascular events in patients with Type 2 Diabetes and elevated triglycerides who are already on statin therapy.

If you have Type 2 Diabetes, high triglycerides, and are already taking a statin for cholesterol, ask your doctor about Icosapent Ethyl (Vascepa). This specific prescription omega-3 fatty acid has been shown to significantly reduce the risk of heart attack and stroke in patients like you. It is not the same as over-the-counter fish oil.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes compared to placebo, other GLP-1 agonists, and insulin.

If you have Type 2 Diabetes, tirzepatide is a highly effective once-weekly injection that lowers blood sugar and helps you lose significant weight, often outperforming other common diabetes medications and insulin. While it can cause temporary stomach issues like nausea, these are usually mild and manageable, and the long-term benefits for your heart, kidneys, and overall metabolic health are substantial.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide, tirzepatide) significantly reduce body weight and improve glycemic control in patients with Type 2 Diabetes and Obesity.

GLP-1 receptor agonists are highly effective for weight loss and blood sugar control in obesity and Type 2 Diabetes. Options include daily or weekly injections and oral tablets. Expect significant weight loss (15-24% depending on the drug) and improved metabolic health. Discuss specific drug choice (e.g., Semaglutide vs. Tirzepatide) with your doctor based on efficacy needs and administration preference.

Tirzepatid (5-15 mg weekly) produces superior HbA1c reduction (mean 1.87-2.59%) and body weight loss (up to 12.9 kg) compared to placebo, semaglutide, and insulin in patients with type 2 diabetes.

Tirzepatid is a once-weekly injection for Type 2 Diabetes that significantly lowers blood sugar (HbA1c) and promotes substantial weight loss, outperforming other common diabetes medications like semaglutide and insulin. It works by mimicking two gut hormones (GIP and GLP-1). Common side effects like nausea are manageable and tend to improve over time. It is approved for adults with T2D, often used alongside metformin or other drugs.

Pharmacological treatment of obesity is ineffective and potentially harmful if not combined with lifestyle changes (calorie restriction and increased energy expenditure), as evidenced by 'stop rules' that mandate discontinuation if <5% weight loss occurs within 12 weeks.

Obesity drugs are not magic. They require you to eat less and move more. If you don't see at least 5% weight loss in 3 months on the full dose, the drug isn't working for you, and you should stop and try something else. Always combine medication with lifestyle changes for the best results.

Tirzepatide produces superior weight loss and glycemic control compared to GLP-1 receptor agonists (e.g., semaglutide) by acting as a balanced dual GIP/GLP-1 receptor agonist, leveraging GIP-mediated effects on adipose tissue metabolism and insulin sensitivity.

Tirzepatide is a once-weekly injectable medication that targets both GLP-1 and GIP receptors. It has been shown to produce significant weight loss (up to 25% in some trials) and improve blood sugar control, often outperforming GLP-1-only drugs. It is prescribed for obesity and type 2 diabetes under medical supervision.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant, sustained weight loss (5-20% body weight reduction) in adults with obesity or overweight with comorbidities, primarily by delaying gastric emptying and reducing central appetite signaling.

If you have obesity or overweight with related health issues, GLP-1 medications like semaglutide or tirzepatide are currently the most effective pharmacological tools available in Europe. They work by mimicking hormones that tell your brain you are full and slowing down digestion. While they require weekly injections and may cause temporary stomach issues, they can lead to significant, sustained weight loss (often 15% or more) when combined with diet and exercise changes. Older weight loss drugs are largely unavailable due to safety risks.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) produces significantly greater weight loss and glycemic control than semaglutide (a GLP-1 receptor agonist) in patients with type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, tirzepatide (Mounjaro/Zepbound) is clinically shown to be more effective for weight loss and blood sugar control than semaglutide (Ozempic/Wegovy). It works by targeting two hormones (GLP-1 and GIP) rather than just one. Expect weekly injections and potential stomach upset initially, which usually improves as your dose increases. Consult your doctor to see if this stronger option is appropriate for your specific health profile.

Subcutaneous semaglutide 2.4 mg administered once weekly reduces the risk of death from cardiovascular causes by 20% in patients with overweight or obesity without diabetes, based on the SELECT trial.

If you have had a heart attack and are overweight or obese but do not have diabetes, ask your doctor about semaglutide 2.4 mg. It is taken once weekly and has been shown to significantly reduce the risk of dying from heart-related causes. Be aware of potential stomach issues and the high cost if not covered by insurance.

Bariatric surgery (Roux-en-Y or Sleeve Gastrectomy) provides superior long-term weight loss and metabolic remission compared to conservative lifestyle interventions alone.

If you have severe obesity and metabolic syndrome, lifestyle changes alone rarely sustain weight loss long-term. Bariatric surgery (like Sleeve or Gastric Bypass) is the most effective treatment, offering nearly 20% total body weight loss and high rates of diabetes/blood pressure remission that diet alone cannot achieve.

Continuous administration of GLP-1/GIP receptor agonists (liraglutide, semaglutide, tirzepatide) produces significant weight loss (6-22%) and cardiovascular risk reduction, but discontinuation leads to rapid weight regain and loss of therapeutic benefits.

Obesity pharmacotherapy with GLP-1/GIP agonists is highly effective for weight loss and cardiovascular health, but it is not a 'cure' with a fixed end date. You must continue the medication long-term to maintain weight loss; stopping leads to rapid regain. Discuss with your doctor whether the benefits of continuous therapy outweigh the burden of daily/weekly injections and potential side effects.

GLP-1 and dual/triple agonist therapies (semaglutide, tirzepatide, retatrutide) produce double-digit mean weight loss (15-24%) in clinical trials, significantly exceeding older pharmacotherapies.

If you have obesity, newer GLP-1 or dual/triple agonist medications can help you lose 15-20% of your body weight, which is significantly more than older drugs. These are taken as weekly injections (or soon, oral pills). You must discuss insurance coverage and potential side effects like nausea with your doctor, as cost and access are major hurdles.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) induce substantial weight loss (10-25%) and improve glycemic control through appetite suppression and enhanced satiety.

GLP-1 and GIP/GLP-1 agonists are highly effective for weight loss, achieving 10-25% reduction. They work by suppressing appetite and increasing satiety. Treatment requires a gradual dose increase to manage common gastrointestinal side effects like nausea. These drugs are indicated for adults with obesity or overweight with comorbidities, and should be used alongside lifestyle changes.

At maximum approved doses, tirzepatide (15 mg) produces significantly greater weight loss and glycemic improvement than semaglutide (2.4 mg).

If you are treating obesity with GLP-1/GIP agonists at their maximum FDA-approved doses, Tirzepatide (15 mg) will likely produce more weight loss and better blood sugar control than Semaglutide (2.4 mg). However, cost and availability may make Semaglutide a more practical first choice for some patients.

Modern incretin-based and multi-agonist peptide therapies (GLP-1, GIP/GLP-1, and triple agonists) induce double-digit percentage weight loss (15-25%) that approaches or exceeds outcomes historically associated with bariatric surgery.

If you have obesity, modern peptide therapies like tirzepatide or semaglutide can help you lose 15-25% of your body weight, which is significantly more than older drugs and approaches the results of surgery. These treatments work by targeting the hormones that control your hunger and metabolism. While they are injectable and can be expensive, they are increasingly considered first-line treatments, especially if you have other health risks like heart disease or diabetes. You should discuss these options with your doctor to see if they are appropriate for you.

Semaglutide 2.4 mg significantly reduces major adverse cardiovascular events (MACE) in individuals with overweight or obesity without diabetes, establishing pharmacological weight loss as cardiovascular risk-modifying therapy.

If you have overweight or obesity but no diabetes, semaglutide 2.4 mg can help reduce your risk of serious heart problems like heart attack and stroke. This benefit is independent of your blood sugar levels. It is an injectable medication taken once a week. You should talk to your doctor about whether this is right for you, especially if you have other cardiovascular risk factors.

Semaglutide (2.4 mg weekly) significantly improves MASH resolution and fibrosis in patients with F2-F3 fibrosis, with benefits extending to significant weight loss and metabolic improvements.

If you have moderate to advanced liver scarring (F2-F3) from metabolic issues, Semaglutide is a new once-weekly injection option. It significantly reduces liver inflammation and scarring, and also promotes weight loss and improves blood sugar and cholesterol. It is generally well-tolerated, though gastrointestinal side effects are common initially.

Semaglutide 2.4 mg/week significantly reduces major adverse cardiovascular events (MACE) in overweight or obese adults with preexisting cardiovascular disease but without diabetes.

If you are overweight or obese and have existing heart disease but no diabetes, ask your doctor about semaglutide 2.4 mg/week. It is the first obesity medication proven to lower the risk of heart attacks, strokes, and cardiovascular death. The treatment involves a weekly injection, starting at a low dose to minimize stomach issues, and has been shown to significantly improve cardiovascular outcomes over standard care alone.

Semaglutide 2.4 mg/week leads to significant weight loss and improvement in cardiovascular risk factors (blood pressure, lipids, inflammation) in overweight or obese adults without diabetes.

Semaglutide 2.4 mg/week helps overweight or obese individuals lose an average of 9.4% of their body weight over 104 weeks, compared to less than 1% with placebo. This weight loss is associated with improvements in blood pressure, cholesterol, and inflammation markers, contributing to better cardiovascular health.

Semaglutide 2.4 mg/week significantly reduces the incidence of new-onset type 2 diabetes and prediabetes in overweight or obese adults without diabetes.

For overweight or obese individuals without diabetes, semaglutide 2.4 mg/week reduces the risk of developing type 2 diabetes by 73% and prediabetes by 67% compared to placebo.

Weight loss interventions, particularly pharmacologic treatments like GLP-1 receptor agonists (e.g., semaglutide, tirzepatide), significantly reduce OSA severity and may reduce cardiovascular disease risk.

If you have sleep apnea and are overweight, losing weight is one of the most powerful things you can do for your heart and your sleep. Modern medications like semaglutide or tirzepatide can help you lose significant weight, which directly reduces the severity of your sleep apnea and your risk of heart disease. Discuss these options with your doctor.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) significantly reduce major adverse cardiovascular events (MACE) and promote substantial weight loss in patients with or without diabetes, addressing core CMS components.

If you have obesity and cardiovascular risk factors, GLP-1 agonists like semaglutide or liraglutide are highly effective. They help you lose significant weight and reduce your risk of heart attacks and strokes. These are typically injected weekly or daily. Discuss with your doctor if you are a candidate, especially if you have obesity-related complications.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces substantial, sustained, and dose-dependent weight loss in adults with obesity, significantly outperforming placebo, semaglutide, and dulaglutide.

If you have obesity, Tirzepatide is a highly effective, once-weekly injection that helps you lose a significant amount of weight (up to 20% or more) by targeting the hormones that control hunger and fullness. It works better than other similar drugs and lifestyle changes alone. While it can cause temporary stomach issues like nausea, these usually get better over time. It is a long-term treatment for a chronic condition.